Impact of ribotype 027 on Clostridium difficile infection in a geriatric department.

Mascart, G;Delmée, Michel;Van Broeck, Johan;Cytryn, E;Cherifi, S;et.al.
(2013) European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology — Vol. 32, n° 9, p. 1177-1182 (2013)

Files

CdifinGeriatricDepartment.pdf
  • Restricted Access
  • Adobe PDF
  • 199.05 KB
Request a copy

Details

Authors
  • Mascart, G
    Author
  • Delmée, MichelUCLouvain
    Author
  • Van Broeck, JohanUCLouvain
    Author
  • Cytryn, E
    Author
  • Cherifi, S
    Author
Show more
Abstract
The purposes of this study were to describe the epidemiology (2001-2009) of Clostridium difficile infections (CDI) in a geriatric department and to compare the clinical data of patients infected with a 027 or non-027 strain. We retrospectively identified all geriatric patients with CDI and analysed the clinical and microbiological data of 133 patients for whom a ribotype was available between March 2003 and December 2009. The incidence of CDI in our geriatric department increased from 0.2 per 100 admissions in 2001 to 8.1 in 2004 and decreased to 1.3 in 2008 before a new rise to 2.1 in 2009. The percentage of ribotype 027 decreased from 2007 but it remained the most prevalent ribotype during the years 2007-2009, with a greater dispersion of ribotypes. The mean age of the patients was 84 years and the median Charlson index was 6.0. Previous use of fluoroquinolones was a significant risk factor for developing a CDI with an 027 strain (p = 0.001). Cure was significantly lower in the 027 group (p = 0.003). The total attributable mortality was 24.1 %. A multiparametric model showed that attributable mortality was influenced by the ribotype 027 (p = 0.037), the severity of clinical symptoms (p = 0.001) and the type of treatment (p = 0.002). Oral vancomycin had a protective effect against mortality. Attention should be paid to elderly patients developing a CDI, especially after the administration of fluoroquinolones. Oral vancomycin could be recommended as the first-line agent not only to protect against recurrence or severe CDI, but to diminish the attributable mortality risk.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Mascart, G., Delmée, M., Van Broeck, J., Cytryn, E., Karmali, R., & Cherifi, S. (2013). Impact of ribotype 027 on Clostridium difficile infection in a geriatric department. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 32(9), 1177-1182. https://doi.org/10.1007/s10096-013-1864-2 (Original work published 2013)